Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports.

Despite the ongoing craze surrounding the GLP-1 obesity drugs, the healthcare sector was a lagger last year. On January 3, Jared Holz, Mizuho Securities America’s healthcare sector strategist ...

Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...

Despite the ongoing craze surrounding the GLP-1 obesity drugs, the healthcare sector was a lagger last year. On January 3, Jared Holz, Mizuho Securities America’s healthcare sector strategist, ...

Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases ---- Amit Munshi ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH) therapy, but new data has dented optimism about the project.

Roche Holding AG Akt-0.44% CHF238.46B ...